160 related articles for article (PubMed ID: 29914143)
21. From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.
Christensen SB; Simonsen HT; Engedal N; Nissen P; Møller JV; Denmeade SR; Isaacs JT
Prog Chem Org Nat Prod; 2021; 115():59-114. PubMed ID: 33797641
[TBL] [Abstract][Full Text] [Related]
22. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Brennen WN; Rosen DM; Wang H; Isaacs JT; Denmeade SR
J Natl Cancer Inst; 2012 Sep; 104(17):1320-34. PubMed ID: 22911669
[TBL] [Abstract][Full Text] [Related]
23. Targeting Toxins toward Tumors.
Franzyk H; Christensen SB
Molecules; 2021 Feb; 26(5):. PubMed ID: 33673582
[TBL] [Abstract][Full Text] [Related]
24. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.
Mahalingam D; Wilding G; Denmeade S; Sarantopoulas J; Cosgrove D; Cetnar J; Azad N; Bruce J; Kurman M; Allgood VE; Carducci M
Br J Cancer; 2016 Apr; 114(9):986-94. PubMed ID: 27115568
[TBL] [Abstract][Full Text] [Related]
25. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
[TBL] [Abstract][Full Text] [Related]
26. Thapsigargin-From Traditional Medicine to Anticancer Drug.
Jaskulska A; Janecka AE; Gach-Janczak K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374919
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Baiz D; Pinder TA; Hassan S; Karpova Y; Salsbury F; Welker ME; Kulik G
J Med Chem; 2012 Sep; 55(18):8038-46. PubMed ID: 22924393
[TBL] [Abstract][Full Text] [Related]
29. Spatiotemporal Concurrent Liberation of Cytotoxins from Dual-Prodrug Nanomedicine for Synergistic Antitumor Therapy.
Zhang L; Qian M; Cui H; Zeng S; Wang J; Chen Q
ACS Appl Mater Interfaces; 2021 Feb; 13(5):6053-6068. PubMed ID: 33525873
[TBL] [Abstract][Full Text] [Related]
30. Melanoma-targeted delivery system (part 1): design, synthesis and evaluation of releasable disulfide drug by glutathione.
El Aissi R; Chezal JM; Tarrit S; Chavignon O; Moreau E
Eur J Med Chem; 2015 Aug; 101():668-80. PubMed ID: 26210505
[TBL] [Abstract][Full Text] [Related]
31. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
33. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Chen Z; Penet MF; Krishnamachary B; Banerjee SR; Pomper MG; Bhujwalla ZM
Biomaterials; 2016 Feb; 80():57-67. PubMed ID: 26706476
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
Naylor MA; Threadgill MD; Showalter HD; Stratford IJ; Stephens MA; Fielden EM; Adams GE
Drug Des Discov; 1993; 10(3):249-55. PubMed ID: 8268395
[TBL] [Abstract][Full Text] [Related]
35. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
38. Towards enzyme activated antiprostatic agents.
Jones GB; Mitchell MO; Weinberg JS; D'Amico AV; Bubley GJ
Bioorg Med Chem Lett; 2000 Sep; 10(17):1987-9. PubMed ID: 10987433
[TBL] [Abstract][Full Text] [Related]
39. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Mhaka A; Denmeade SR; Yao W; Isaacs JT; Khan SR
Bioorg Med Chem Lett; 2002 Sep; 12(17):2459-61. PubMed ID: 12161157
[TBL] [Abstract][Full Text] [Related]
40. Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release.
Romanucci V; Giordano M; Pagano R; Zimbone S; Giuffrida ML; Milardi D; Zarrelli A; Di Fabio G
Bioorg Med Chem; 2021 Nov; 50():116478. PubMed ID: 34695708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
